NCT06172322View on ClinicalTrials.gov

A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 28, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

July 31, 2025

Conditions

HR Positive/HER-2 Negative Breast Cancer

Interventions

DRUG

NTQ1062 with Fulvestrant

"Drug: NTQ1062 tablet(s) ，PO，QD in cycles of 28 days (21 days on treatment followed by 7 days off treatment).~Drug: Fulvestrant Injection 500mg in a 28-day cycle."

Trial Locations (1)

201321

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai